These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21371182)

  • 21. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
    Shortt J; Dunkley S; Rickard K; Baker R; Street A
    Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.
    Federici AB; Barillari G; Zanon E; Mazzucconi MG; Musso R; Targhetta R; Mannucci PM
    Haemophilia; 2010 Jan; 16(1):101-10. PubMed ID: 19811543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
    Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract]   [Full Text] [Related]  

  • 27. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).
    Skotnicki A; Lissitchkov TJ; Mamonov V; Buevich E; Kuliczkowski K; Goranov S; Kłoczko J; Klukowska A; Stankovic S; Gercheva L; Chernova T; Hellmann A; Dmoszyńska A; Zawilska K; Veldman A; Joch C; Seifert W
    Thromb Res; 2016 Jan; 137():119-125. PubMed ID: 26614676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis.
    Quon DV; Logan L
    Haemophilia; 2011 Jan; 17(1):e196-201. PubMed ID: 20618876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.
    Nitu-Whalley IC; Griffioen A; Harrington C; Lee CA
    Am J Hematol; 2001 Apr; 66(4):280-4. PubMed ID: 11279640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
    Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peri-operative management of an adult patient with type 2N von Willebrand's disease scheduled for coronary artery bypass graft.
    Gerling V; Lahpor JR; Buhre W
    Anaesthesia; 2007 Apr; 62(4):405-8. PubMed ID: 17381580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
    Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.
    Klamroth R; Holzhauer S; Zimmermann R; Heller C; Kurnik K;
    Thromb Res; 2014 Nov; 134 Suppl 1():S16-21. PubMed ID: 24418255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.
    Windyga J; Rusen L; Gruppo R; O'Brien AC; Kelly P; Roth DA; Arkin S
    Haemophilia; 2010 Sep; 16(5):731-9. PubMed ID: 20412322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies.
    Mauser-Bunschoten EP; Kleine Budde I; Lopaciuk S; Koopman MM; Van Der Meer FJ; Novàkovà IR; Ypma P; Van Der Linden PW; Windyga J; Strengers PF
    Haemophilia; 2011 May; 17(3):439-45. PubMed ID: 21362109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.